• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Entrada Therapeutics Inc (NQ: TRDA )

    19.82 +0.59 (+3.07%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Entrada Therapeutics Inc

    < Previous 1 2 3 4 Next >
    Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
    Via Benzinga
    Entrada Therapeutics Reports Third Quarter 2024 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Recap: Entrada Therapeutics Q4 Earnings
    Via Benzinga
    Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024
    TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Entrada Therapeutics Reports Second Quarter 2024 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Announces $100 Million Registered Direct Offering
    – The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – 
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024
    TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Entrada Therapeutics Reports First Quarter 2024 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Insiders Buying America's Car-Mart And 2 Other Stocks
    Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
    Via Benzinga
    Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
    Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
    Via Benzinga
    Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics to Present at Upcoming Investor Conferences
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Promotes Nathan J. Dowden to President
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
    Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in  
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Reports Third Quarter 2023 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics to Present at Upcoming Investor Conferences
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics to Present at Upcoming Investor Conferences
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.